Aclarion, Inc. (ACON) Dividend History

Aclarion, Inc. (ACON) is a company focused on developing and commercializing innovative medical devices, particularly in the field of neurotechnology. They aim to improve target engagement and patient outcomes through advanced solutions that facilitate precise neurostimulation and neurofeedback.

8181 Arista Place, Broomfield, CO, 80021
Phone: 833 275 2266
Website: https://www.aclarion.com

Dividend History

Aclarion, Inc. currently does not pay dividends

Company News

Aclarion Announces Addition of Keck Medical Center of USC as CLARITY Trial Site

Aclarion, Inc. announced that the USC Spine Center, part of Keck Medicine of USC, has joined the CLARITY clinical trial to evaluate Nociscan, Aclarion's technology that uses MR Spectroscopy and AI to identify sources of chronic low back pain.

GlobeNewswire Inc.
Aclarion Releases Updated Investor Presentation in Connection with Appearance at Planet MicroCap Showcase: VEGAS 2025

Aclarion, a healthcare technology company, will be presenting at the Planet MicroCap Showcase: VEGAS 2025 and has published an updated investor presentation. The company's Nociscan platform uses MRS, biomarkers, and AI to help physicians identify the location of chronic low back pain.

GlobeNewswire Inc.
Aclarion Announces Publication of Seminal Nociscan Cost-Effectiveness Analysis

An independent analysis found that Aclarion's Nociscan solution is more cost-effective and improves surgical success by 10% compared to provocative discography for identifying the source of chronic low back pain.

GlobeNewswire Inc.
Aclarion Announces First Commercial Agreement with Scripps Health

Aclarion, a healthcare technology company, has established a commercial agreement with Scripps Health in San Diego to bring its Nociscan technology to the region. Nociscan uses MR Spectroscopy and AI to help physicians identify the location of chronic low back pain.

GlobeNewswire Inc.
Aclarion, Inc. Announces Adjournment of Special Meeting of Stockholders

Aclarion, Inc. announced the adjournment of its Special Meeting of Stockholders to March 5, 2025, to solicit additional votes on the proposals described in its proxy statement. The company is leveraging Magnetic Resonance Spectroscopy, AI, and a proprietary biomarker to optimize treatments for low back and neck pain.

GlobeNewswire Inc.

Dividend data last updated 06/06/2025 23:03:46 UTC